{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T03:02:37Z","timestamp":1790996557561,"version":"4.1.0"},"reference-count":55,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2018,10,31]],"date-time":"2018-10-31T00:00:00Z","timestamp":1540944000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0205897","type":"journal-article","created":{"date-parts":[[2018,10,31]],"date-time":"2018-10-31T13:44:34Z","timestamp":1540993474000},"page":"e0205897","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":34,"title":["Anticholinergic burden in adult and elderly people with intellectual disabilities: Results from an Italian multicenter cross-sectional study"],"prefix":"10.1371","volume":"13","author":[{"given":"Luc Pieter","family":"De Vreese","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrico","family":"Mantesso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"De Bastiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annachiara","family":"Marangoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Weger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2931-9571","authenticated-orcid":true,"given":"Tiziano","family":"Gomiero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2018,10,31]]},"reference":[{"key":"ref1","article-title":"Goodman &amp; Gilman\u2019s The Pharmacological Basis of Therapeutics","author":"J Brown","year":"2011"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s40520-015-0359-7","article-title":"Anticholinergic drugs and negative outcomes in the older population: from biological plausibility to clinical evidence","volume":"Vol. 28","author":"A Collamati","year":"2016","journal-title":"Aging Clinical and Experimental Research"},{"issue":"2","key":"ref3","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/bcp.12617","article-title":"Drugs with anticholinergic effects and cognitive impairment, falls and all-cause mortality in older adults: A systematic review and meta-analysis","volume":"80","author":"K Ruxton","year":"2015","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"ref4","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1177\/2042098616658399","article-title":"Anticholinergic medication use and dementia: latest evidence and clinical implications","volume":"7","author":"SL Gray","year":"2016","journal-title":"Ther Adv Drug Saf"},{"issue":"3","key":"ref5","doi-asserted-by":"crossref","first-page":"e00310","DOI":"10.1002\/prp2.310","article-title":"Anticholinergic drug exposure is associated with delirium and postdischarge institutionalization in acutely ill hospitalized older patients","volume":"5","author":"A Egberts","year":"2017","journal-title":"Pharmacol Res Perspect"},{"issue":"2","key":"ref6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0171353","article-title":"Anticholinergic burden and cognitive function in a large German cohort of hospitalized geriatric patients","volume":"12","author":"B Pfistermeister","year":"2017","journal-title":"PLoS One"},{"issue":"4","key":"ref7","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.ridd.2014.01.022","article-title":"Multimorbidity in older adults with intellectual disabilities","volume":"35","author":"H Hermans","year":"2014","journal-title":"Res Dev Disabil"},{"issue":"3","key":"ref8","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1352\/1944-7558-119.3.253","article-title":"Epidemiology of Epilepsy in Older Adults With an Intellectual Disability in Ireland: Associations and Service Implications","volume":"119","author":"M McCarron","year":"2014","journal-title":"Am J Intellect Dev Disabil"},{"key":"ref9","article-title":"Reduction or discontinuation of antipsychotics for challenging behaviour in adults with intellectual disability: a systematic review","author":"R Sheehan","year":"2016","journal-title":"The Lancet Psychiatry"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1177\/2042098618782785","article-title":"Medication use and potentially inappropriate prescribing in older adults with intellectual disabilities: a neglected area of research","volume":"9","author":"M O\u2019Dwyer","year":"2018","journal-title":"Ther Adv Drug Saf"},{"issue":"2","key":"ref11","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.bbr.2010.11.058","article-title":"The cholinergic system in aging and neuronal degeneration","volume":"221","author":"R Schliebs","year":"2011","journal-title":"Behav Brain Res"},{"key":"ref12","first-page":"1","article-title":"Association of anticholinergic burden with adverse effects in older people with intellectual disabilities: an observational cross-sectional study","author":"M O\u2019Dwyer","year":"2016","journal-title":"Br J Psychiatry"},{"issue":"2","key":"ref13","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/sj.clpt.6100035","article-title":"Anticholinergic Drugs and Physical Function Among Frail Elderly Population","volume":"81","author":"F Landi","year":"2007","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"ref14","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s40266-012-0044-x","article-title":"Association of Anticholinergic Burden with Cognitive and Functional Status in a Cohort of Hospitalized Elderly: Comparison of the Anticholinergic Cognitive Burden Scale and Anticholinergic Risk Scale","volume":"30","author":"L Pasina","year":"2013","journal-title":"Drugs Aging"},{"issue":"11","key":"ref15","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.jamda.2014.08.002","article-title":"Anticholinergic Drug Use and Negative Outcomes Among the Frail Elderly Population Living in a Nursing Home","volume":"15","author":"F Landi","year":"2014","journal-title":"J Am Med Dir Assoc"},{"issue":"4","key":"ref16","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s12603-016-0787-x","article-title":"Anticholinergic burden and functional status in older people with cognitive impairment: Results from the ReGAl project","volume":"21","author":"V Boccardi","year":"2017","journal-title":"J Nutr Health Aging"},{"key":"ref17","unstructured":"Aging Brain Care. Anticholinergic Cognitive Burden Scale [Internet]. 2012. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.agingbraincare.org\/uploads\/products\/ACB_scale_-_legal_size.pdf\" xlink:type=\"simple\">www.agingbraincare.org\/uploads\/products\/ACB_scale_-_legal_size.pdf<\/ext-link>. Accessed 2017 Nov 4."},{"key":"ref18","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1212\/WNL.0b013e3181e7f2ab","article-title":"Use of anticholinergics and the risk of cognitive impairment in an African-American population","volume":"75","author":"NL Campbell","year":"2010","journal-title":"Neurology"},{"issue":"3","key":"ref19","doi-asserted-by":"crossref","first-page":"311","DOI":"10.2217\/1745509X.4.3.311","article-title":"Impact of anticholinergics on the aging brain: a review and practical application","volume":"4","author":"M Boustani","year":"2008","journal-title":"Aging health"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s12877-015-0029-9","article-title":"Anticholinergic burden quantified by anticholinergic risk scales and adverse outcomes in older people: a systematic review","volume":"15","author":"MS Salahudeen","year":"2015","journal-title":"BMC Geriatr"},{"issue":"2","key":"ref21","first-page":"33","article-title":"Pharmacotherapy in adult and elderly persons with intellectual disabilities: results of a multicenter study","author":"LP De Vreese","year":"2016","journal-title":"Psicogeriatria"},{"issue":"6","key":"ref22","first-page":"1","article-title":"A multicentre Italian validation study in aging adults with Down syndrome and other forms of Intellectual Disabilities: Dementia Screening Questionnaire for Individuals with Intellectual Disabilities","volume":"14","author":"T Gomiero","year":"2017","journal-title":"Curr Alzheimer Res"},{"issue":"3","key":"ref23","first-page":"19","article-title":"A reliability study of the Italian version of DMR","author":"LP De Vreese","year":"2007","journal-title":"Psicogeriatria"},{"issue":"8","key":"ref24","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.mayocp.2013.04.024","article-title":"The National Task Group on Intellectual Disabilities and Dementia Practices Consensus Recommendations for the Evaluation and Management of Dementia in Adults With Intellectual Disabilities","volume":"8","author":"JA Moran","year":"2013","journal-title":"Mayo Clin Proc"},{"issue":"2","key":"ref25","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/j.1365-2788.1997.tb00692.x","article-title":"Diagnosis of dementia in individuals with intellectual disability","volume":"41","author":"EH Aylward","year":"1997","journal-title":"J Intellect Disabil Res"},{"issue":"2","key":"ref26","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1352\/0895-8017(2004)109<111:DIAWMR>2.0.CO;2","article-title":"Dementia in adults with mental retardation: assessment at a single point in time","volume":"109","author":"W Silverman","year":"2004","journal-title":"Am J Ment Retard"},{"issue":"2","key":"ref27","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/j.1532-5415.1995.tb06377.x","article-title":"Validation of the Cumulative Illness Rating Scale in a geriatric residential population","volume":"43","author":"P Parmelee","year":"1995","journal-title":"J Am Geriatr Soc"},{"key":"ref28","unstructured":"World Health Organization. World report on ageing and health. 2015. Geneve; 2015. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.who.int\/ageing\/publications\/world-report-2015\/en\/\" xlink:type=\"simple\">http:\/\/www.who.int\/ageing\/publications\/world-report-2015\/en\/<\/ext-link>"},{"issue":"1","key":"ref29","doi-asserted-by":"crossref","DOI":"10.1517\/14740338.2013.827660","article-title":"Clinical Consequences of Polypharmacy in Elderly","volume":"13","author":"RL Maher","year":"2014","journal-title":"Expert Opin Drug Saf"},{"issue":"4","key":"ref30","doi-asserted-by":"crossref","first-page":"e010505","DOI":"10.1136\/bmjopen-2015-010505","article-title":"Factors associated with polypharmacy and excessive polypharmacy in older people with intellectual disability differ from the general population: a cross-sectional observational nationwide study","volume":"6","author":"M O\u2019Dwyer","year":"2016","journal-title":"BMJ Open"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"h4326","DOI":"10.1136\/bmj.h4326","article-title":"Mental illness, challenging behaviour, and psychotropic drug prescribing in people with intellectual disability: UK population based cohort study","volume":"351","author":"R Sheehan","year":"2015","journal-title":"BMJ"},{"key":"ref32","article-title":"Dementia and people with intellectual disabilities: Guidance on the assessment, diagnosis, interventions and support of people with intellectual disabilities who develop dementia","year":"2015"},{"issue":"2","key":"ref33","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s40266-014-0236-7","article-title":"Pharmacological Management of Behavioral and Psychiatric Symptoms in Older Adults with Intellectual Disability","volume":"32","author":"N Eady","year":"2015","journal-title":"Drugs Aging"},{"issue":"3","key":"ref34","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1345\/aph.1Q597","article-title":"Institutionalization as a Risk Factor for Inappropriate Drug Use in the Elderly: A Swedish Nationwide Register-Based Study","volume":"46","author":"Y Haasum","year":"2012","journal-title":"Ann Pharmacother"},{"issue":"2","key":"ref35","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.cger.2012.01.005","article-title":"Outcomes of Polypharmacy in Nursing Home Residents","volume":"28","author":"BK Tamura","year":"2012","journal-title":"Clin Geriatr Med"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"757","DOI":"10.2147\/TCRM.S117321","article-title":"Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review","volume":"13","author":"M Solmi","year":"2017","journal-title":"Ther Clin Risk Manag"},{"issue":"6","key":"ref37","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.ridd.2006.08.002","article-title":"Prevalence and risk factors of constipation in adults with intellectual disability in residential care centers in Israel","volume":"28","author":"M Morad","year":"2007","journal-title":"Res Dev Disabil"},{"issue":"3","key":"ref38","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s11938-017-0142-2","article-title":"Intractable Constipation in the Elderly","volume":"15","author":"N Baffy","year":"2017","journal-title":"Curr Treat Options Gastroenterol"},{"issue":"4","key":"ref39","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.seizure.2010.12.011","article-title":"Gastrointestinal adverse effects of antiepileptic drugs in intractable epileptic patients","volume":"20","author":"SR Jahromi","year":"2017","journal-title":"Seizure\u2014Eur J Epilepsy"},{"issue":"3","key":"ref40","doi-asserted-by":"crossref","first-page":"138","DOI":"10.6000\/2292-2598.2015.03.03.3","article-title":"The Assessment of Psychiatric Disorders in Intellectual Disability: The State of the Art","volume":"3","author":"M Bertelli","year":"2015","journal-title":"J Intellect Disabil\u2014Diagnosis Treat"},{"issue":"10","key":"ref41","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1111\/jir.12385","article-title":"Physicians\u2019 reasons not to discontinue long-term used off-label antipsychotic drugs in people with intellectual disability","volume":"61","author":"GM de Kuijper","year":"2017","journal-title":"J Intellect Disabil Res"},{"issue":"6","key":"ref42","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1001\/jamaneurol.2016.0580","article-title":"Association Between Anticholinergic Medication Use and Cognition, Brain Metabolism, and Brain Atrophy in Cognitively Normal Older Adults","volume":"73","author":"SL Risacher","year":"2016","journal-title":"JAMA Neurol"},{"issue":"9","key":"ref43","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/nrn3983","article-title":"A genetic cause of Alzheimer disease: mechanistic insights from Down syndrome","volume":"16","author":"FK Wiseman","year":"2015","journal-title":"Nat Rev Neurosci"},{"issue":"9","key":"ref44","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1111\/jir.12390","article-title":"A prospective 20-year longitudinal follow-up of dementia in persons with Down syndrome","volume":"61","author":"M McCarron","year":"2017","journal-title":"J Intellect Disabil Res"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"g4323","DOI":"10.1136\/bmj.g4323","article-title":"Drug treatments in people with intellectual disability and challenging behaviour","volume":"349","author":"P Tyrer","year":"2014","journal-title":"BMJ"},{"issue":"8","key":"ref46","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1177\/1756285617712979","article-title":"Best practice in the management of behavioural and psychological symptoms of dementia","volume":"10","author":"OP Tible","year":"2017","journal-title":"Ther Adv Neurol Disord"},{"issue":"1","key":"ref47","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1365-2788.2012.01631.x","article-title":"Effects of controlled discontinuation of long-term used antipsychotics for behavioural symptoms in individuals with intellectual disability","volume":"58","author":"GM de Kuijper","year":"2014","journal-title":"J Intellect Disabil Res"},{"key":"ref48","article-title":"Reduction of the Anticholinergic Burden Makes It Possible to Decrease Behavioral and Psychological Symptoms of Dementia","author":"Y Ja\u00efdi","year":"2017","journal-title":"Am J Geriatr Psychiatry"},{"issue":"11","key":"ref49","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1111\/jgs.13702","article-title":"American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults","volume":"63","year":"2015","journal-title":"J Am Geriatr Soc"},{"issue":"2","key":"ref50","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/ageing\/afu145","article-title":"STOPP\/START criteria for potentially inappropriate rescribing in older people: version 2","volume":"44","author":"D O\u2019Mahony","year":"2015","journal-title":"Age Ageing"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.2147\/CIA.S135481","article-title":"Development of a core outcome set for medication review in older patients with multimorbidity and polypharmacy: a study protocol","volume":"12","author":"J-B Beuscart","year":"2017","journal-title":"Clin Interv Aging"},{"issue":"4","key":"ref52","doi-asserted-by":"crossref","first-page":"e013800","DOI":"10.1136\/bmjopen-2016-013800","article-title":"Deprescribing anticholinergic and sedative medicines: protocol for a Feasibility Trial (DEFEAT-polypharmacy) in residential aged care facilities","volume":"7","author":"N Ailabouni","year":"2017","journal-title":"BMJ Open"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ridd.2015.11.017","article-title":"Adverse events and the relation with quality of life in adults with intellectual disability and challenging behaviour using psychotropic drugs","volume":"49\u201350","author":"A Scheifes","year":"2016","journal-title":"Res Dev Disabil"},{"issue":"Supplement C","key":"ref54","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ridd.2016.03.014","article-title":"Medication review using a Systematic Tool to Reduce Inappropriate Prescribing (STRIP) in adults with an intellectual disability: A pilot study","volume":"55","author":"RJ Zaal","year":"2016","journal-title":"Res Dev Disabil"},{"issue":"S1","key":"ref55","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s00702-014-1219-x","article-title":"Polypharmacy in the treatment of subjects with intellectual disability","volume":"122","author":"F H\u00e4\u03b2ler","year":"2015","journal-title":"J Neural Transm"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0205897","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T15:05:43Z","timestamp":1588950343000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0205897"}},"subtitle":[],"editor":[{"given":"Therese","family":"van Amelsvoort","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2018,10,31]]},"references-count":55,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2018,10,31]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0205897","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,31]]}}}